Actionable Intelligence and Insights on China Markets When You Need It
Red Pulse is a market intelligence platform covering China's economy and capital markets.
We connect industry experts, practitioners, and professionals together to share their insights and analyses to a global audience.
Research & Insights
Unlimited Access to Research Notes on China Companies, Sectors, Events and Macro Economy.
  • Timely
    Consistently faster coverage of
    events impacting markets versus
    mainstream media.
  • Relevant
    Vetting market news and events
    while filtering out market rumors
    and propaganda.
  • Actionable
    Focused on covering events
    that impact stocks, funds and
    overall market.
China Expert Network
Interact with our network of China market experts by requesting a range of custom research services through our Expert Network platform. We provide a streamlined process for connecting you with experts in China's various industries, allowing you to gain deeper insights, work through complex challenges, and receive expert feedback.
Latest Insights
  • 6H
    4.25
    NMPA to Accelerate Approvals of High-Demand, Rare Diseases Drugs
    Healthcare
  • 6H
    4.00
    Tencent Holdings to Acquire Gaming Giant Nexon Through NXC
    Technology
  • 7H
    4.33
    China Moly Increases Stake in Congo's Tenke Copper Mine
    Basic
  • 8H
    4.33
    EU Imposes Tariffs on Chinese Electric Bicycles
    Consumer
  • 8H
    4.33
    MoF Issues Tax Cut Policy for Small and Micro Enterprises
    Healthcare
  • 9H
    5.00
    Guangdong Starts Operation of Its First Microgrid
    Industrials
  • 9H
    4.67
    Sinopec Signs JV to Build New LNG Terminals in Shandong
    Industrials
  • 9H
    4.50
    Tencent to Invest RMB1bn in Online Tutoring Business
    Industrials
  • 10H
    4.50
    Huawei Investing USD100bn to Rebuild its Network System
    Healthcare
  • 11H
    4.60
    China's 4Q18 GDP Growth Slips to 6.4% YoY
NMPA to Accelerate Approvals of High-Demand, Rare Diseases Drugs
4.25
8 ratings

Written by Della Liu

Published at 2019-01-21 08:57

The National Medical Products Administration (NMPA) has released plans to facilitate the approval processes for highly clinical demanded and rare disease medicines, and R&D of new drugs in the new year, as reported by Yicai on January 21. Meanwhile, the authority will also put emphasis on the reform of government services in the medical and pharmaceutical industry, the enhancement of the legal system, and supervision over security and high-risk products. For marketed drugs, NMPA intends to revise laws related to the production, distribution, inspection, and detection of drugs, refine the management procedures, strengthen the regulations of vaccine manufacturing, and improve the information traceability system.